Wow - excellent discussion of the totally underwhelming BICAR-ICU2 trial podcasts.apple.com/ca/podcast/f... @nephcrit.bsky.social fighting a line fight against the unimpressed nephrons with guest @weddellite.bsky.social #NephSky #EMIMCC

Safety and Effectiveness of Long-term #Isoniazid Treatment for the #Prevention of #Tuberculosis in High-risk #Dialysis Patients #VisualAbstract by Cristina Popa https://www.kireports.org/article/S2468-0249(25)00733-8/fulltext

A #FIDELITY Analysis on #Finerenone With #SGLT2i and #GLP1RA in CKD #VisualAbstract by Cristina Popa https://www.kireports.org/article/S2468-0249(25)00715-6/fulltext

The Impact of #Homelessness on #Kidney #Outcomes Among Adults With #Diabetes #VisualAbstract by Cristina Popa https://www.kireports.org/article/S2468-0249(25)00718-1/fulltext

1/10 Last #NephJC we discussed dialysis frequency in AKI-D #TenPostNephJC We sought to answer an age-old question: Is less is really more? Or less is just simply what it is….less? pubmed.ncbi.nlm.nih.gov/41201895/

We really don’t think BigPAK makes sense From our journal club at @uottawa.ca into a #NephJC shorts www.nephjc.com/news/2025/12...

We are then going back to our regularly scheduled programming 1/13/26 at 9pm EST VALIANT: Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. #NephJC www.nejm.org/doi/ful...#NephJC

T1a Population: stable AKI-D patients with realistic renal recovery potential Exactly the “gray zone” group we debate daily whether dialysis continuation is necessary. 👀Check out the inclusion/exclusion criteria #NephJC

www.nephjc.com/news/... Check out the excellent #NephJC summary by @msocomd.bsky.social and @sejalplakhani.bsky.social

Hi! Cristina Popa here 👋 #NephJC No COIs. Never practiced 3xHD per week in AKI It’s harder to be awake at this hour when on vacation (although it’s only 3 am 🥱). Here are some pics👇

👉 New to #NephJC ? Check out the infographic by @sstoneman.bsky.social on how this all works. Let’s make this fun, fast, and global 🌏

T-120 min ⏰ 2 hours until #NephJC Tonight’s topic: Dialysis frequency. For AKI-D (AKI requiring dialysis), should we: 🗓️ Dialyze everyone thrice weekly ? or 🧘‍♂️ Dialyze only when needed? The LIBERATE-D RCT tests this long-standing dogma. Does less dialysis = more recovery? 🤯

Gracias! @dramiliflores.bsky.social #NephSky LIBERATE-D: El Resumen Visual — #NephJC www.nephjc.com/news/2025/12/14/liberate-d-el-resumen-visual

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳 How soon should we withhold dialysis in AKI? We're discussing the LIBERATE-D trial #NephSky This one might just change your mind 🧠🧠 Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social www.nephjc.com/news/liberated-aki

The LIBERATE-D VA by @sejalplakhani.bsky.social Should we break the pattern of thrice weekly dialysis in AKI-D? #NephJC #NephSky www.nephjc.com/news/liberateva

11/10 Up next 12/16/25 we’re talking about AKI and best strategies for renal recovery from dialysis #nephjc LIBERATE-D, simultaneous @jama.com publication during #KidneyWk pubmed.ncbi.nlm.nih.gov/41201895/

1/10 Welcome to #TenPostNephJC Last #NephJC we discussed the PISCES study 🐟 on the role of fish oil on cardiovascular events in hemodialysis patients. This study was presented at Kidney Week with simultaneous publication, and was as unexpected as a shark attack🦈.

Our take on the baxdrostat PA trial in @asnpublications.bsky.social #KidneyNews www.kidneynews.org/view/journal... with @nephroseeker.medsky.social and @dramiliflores.bsky.social ! Thanks to Sam Kant and @kdjhaveri.bsky.social for the invite!!

Transplant coming with ….rabies from a 🦨 with an unfortunately fatal outcome for one (and all other transplanted organs being removed) www.nytimes.com/2025/12/06/h... gift link h/t @boback.bsky.social #NephSky #OrganTransplant

Hyponatremia: Diagnostic algorithm from @kidneyboy.bsky.social #Nephpearls #NephSky 👉 shop.lww.com/Handbook-of-...

A new web-based tool called TraceOrg has been developed to accurately measure kidney, liver, and cyst volumes in patients with autosomal dominant polycystic kidney disease (ADPKD) using MRI scans. Read more in #ASNJASN: kidney.pub/JASN0904#ASNJASN:

Circulating #Testican-2 and #MGT5A are Markers of #Membranous Nephropathy #VisualAbstract by Cristina Popa https://www.kireports.org/article/S2468-0249(25)00705-3/fulltext

If you want to stay on top of #NephJC happenings, sign up for our once-a-week newsletter. BONUS: If you sign up now you can vote for TOP STORIES OF 2025!! www.nephjc.com/newsl...

Indeed! We did not know what to expect, but hopeful. Having worked on this for over a decade, I was initially "stunned" by the result but then not really surprised given the multitude of potential effects of EPA and DHA on the cardiovasculature, and our HD patients deficiencies in it #NephJC

We did a lot of sensitivity analyses (see Supplement) using various methods of recurrent event analysis that showed consistent results. Didn't matter how you sliced the fish!

Td Fish oils have been studied in CKD, including: #NephJC SLE, diabetic kidney disease, IgAN, kidney stones, post kidney transplant, CKD progression Oxidative stress and inflammatory states. Are you a frequent fish oil prescriber?

T0c In one meta-analysis of 113 studies 🐟: #NephJC 46.0% reported statistically significant positive results (22 in🫀, 14 in🧠 & 16 in other organs) 31.0% reported results that were not statistically significant (7 in🫀, 18 in 🧠 & 10 in other) 21.2% reported a mixed results

🎨Beautiful visual abstract by Dr Brian Rifkin @brianrifkin.bsky.social #NephJC

Although, you admired the very beautiful visual abstract made by @brianrifkin.bsky.social, #NephJC team (ha, @nephroseeker.medsky.social ) loved fish oil so much that made another one, right after #KidneyWk simultaneous publication 🎣 www.nephjc.com/news/...

The simplest rule is to be kind and inclusive while you use your wit! Here are #NephJC values, summarized by @sstoneman.bsky.social

Hi, #NephJC Cristina Popa, 🇷🇴 nephrologist 💤4 am on my timezone, a bit sleepy, but the fishy smell will keep me awake 🎄Pics from my last weekend trip to Bucharest

Holy Mackerel! 🐟 🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴‍☠️ #NephJC Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST Check out the PISCES VA by @brianrifkin.bsky.social www.nephjc.com/news/piscesva

Maybe the most shocking study from #KidneyWk. 🐚From the depths of the oceans to #BlueSky, we're discussing PISCES 🐟 12/2/25 9pm EST. #NephJC Are you hooked🪝on fish oil for CV disease in ESRD, or are you throwing it back 🌊? www.nephjc.com/news/pisces-fishoil

This is so exciting 🤩 Just a reminder that many big things in medicine started from case reports

Me too. Unfortunately, nephrology was stagnant for too long, community docs stopped paying attention. Now if you’re not paying attention you get left behind. #NephJC tries to focus on new, relevant & patient centered/practice changing studies. Plus so many ways to learn: blog, podcast, chat.

Still full after yesterday's #Thanksgiving feast? Be grateful & share the love to fill bellies in need IT'S #HCWvsHunger TIME!!! hcwvshunger.org for the 🍎 details! 🤩Team #UrineItToWinIt will shine 🤩 @kidneyboy.bsky.social @nephroseeker.medsky.social @hswapnil.medsky.social @mcstarr1.bsky.social

Join the Filtrate and Jon Barratt as he takes an IgAN inspired victory lap FF 86 Atacicept for IgAN www.nephjc.com/freelyfilter...

Sibeprenlimab: First @fda.gov approved therapy targeting B cells which produce the abnormal antibodies responsible for #IgAN, addressing the fundamental cause #Nephpearls #NephSky #VisualAbstract by @nephroseeker.medsky.social 👉🏼 www.fda.gov/drugs/news-e... 👉🏼 pubmed.ncbi.nlm.nih.gov/41211929/

The lineup of the #TopNephrology stories is live www.nephjc.com/news/2025/11... If you want to vote, you need to be signed up for the #NephJC Newsletter here www.nephjc.com/newsletter ASAP

Apixaban and warfarin being similar is also a red flag And with LAOO is such a huge selection bias The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly #NephSky

👇Here are the proposals for the #TopNephrology stories in 2025 🔥 Remember, you can only vote for your favorites if you have subscribed to #NephJC newsletter 📬 Soon we'll send you the voting link. Check your email. www.nephjc.com/news/2025/11...

It began in 2021, wondering why anyone would pick me for #NSMC. I applied in '22 and was surprised to be accepted. I’ve grown thanks to many of you (@hswapnil.medsky.social @kidneyboy.bsky.social ), though I still feel like a newcomer 😊 🙏 Grateful to be in this with @brianrifkin.bsky.social #NephJC

Probably #nephsky will never see a trial comparing spironolactone with finerenone Target emulated trial: potential benefits of finerenone in all sorts of outcomes, but we’re comparing 🔝methodology trials (FIGARO, FIDELIO) vs invetigator initiated trials pubmed.ncbi.nlm.nih.gov/41173939/

#NephJCshort on BICAR-ICU2 #Medsky #Nephsky ✍️ By @nephroseeker.medsky.social 🎭 Bicarbonate makes the picture look cleaner: better pH, more time. But beneath the smoother numbers, the patient hasn't changed. It's the same story, just told in softer colors www.nephjc.com/news/2025/10...

In older patients with frailty who were receiving antihypertensive drugs and had a systolic blood pressure below 130 mm Hg, reducing antihypertensive drugs did not lead to lower all-cause mortality over 4 years than usual care. Full RETREAT-FRAIL trial results and Research Summary: nej.md/45NUK9v

🧵 New #Skeetorial Drop! 🧵 1/ Hey #NephSky! 👋 We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into: Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔 Let’s unpack what this trial means for your next CKD patient. 💊💭